(5Z)-5-{[5-(4-chlorophenyl)furan-2-yl]methylidene}-3-[2-(4-methylphenyl)-2-oxoethyl]-1,3-thiazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (5Z)-5-{[5-(4-chlorophenyl)furan-2-yl]methylidene}-3-[2-(4-methylphenyl)-2-oxoethyl]-1,3-thiazolidine-2,4-dione
• 英文别名: (5Z)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-3-[2-(4-methylphenyl)-2-oxoethyl]-1,3-thiazolidine-2,4-dione
• 化学式: C₂₃H₁₆ClNO₄S
• 分子量: 437.9
• InChiKey: CGYYIFBEGMCBSD-MTJSOVHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  92.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Compounds and methods for regulating integrins
  申请人：ADHAERE PHARMACEUTICALS, INC.

  公开号：US10239871B2

  公开（公告）日：2019-03-26

  A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.

  一种治疗炎症的方法，通过向患者施用有效量的β2整合素激动剂来减轻炎症。一种治疗癌症的方法，向患者施用有效量的β2整合素激动剂，减少肿瘤生长。一种治疗暴露于辐射的患者的方法，方法是在患者暴露于辐射后向其施用有效量的β2整合素激动剂，并减轻辐射对患者的影响。一种预防辐射影响的方法，通过在辐照前向患者施用有效量的β2整合素激动剂，预防辐照对患者的影响。一种治疗获得性骨髓衰竭（BMF）的方法，向患者施用有效量的β2整合素激动剂。改善患者受损血管健康状况并激活β2整合素的方法。
• PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18
  申请人：GB006, Inc.

  公开号：EP3243821B1

  公开（公告）日：2020-02-26
• Compounds and Methods for Regulating Integrins
  申请人：Gupta Vineet

  公开号：US20120010255A1

  公开（公告）日：2012-01-12

  The application describes small molecules capable of modulating activity of beta2 family of integrins, such as integrin CD11b/CD18 (also known as Mac-1, CR3 and αMβ2). Such compounds may be used in certain embodiments for treating a disease or condition, such as inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, wound-healing, organ transplantation and cardiovascular disease, among others.
• COMPOUNDS AND METHODS FOR REGULATING INTEGRINS
  申请人：ADHAERE PHARMACEUTICALS, INC.

  公开号：US20150105435A1

  公开（公告）日：2015-04-16

  A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.
• COMPOUNDS AND METHODS FOR REGULATING INTEGRINS
  申请人：ADHAERE PHARMACEUTICALS, INC.

  公开号：US20160151336A1

  公开（公告）日：2016-06-02

  A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.